PL2875013T3 - Indolokarbonitryle jako selektywne modulatory receptora androgenowego - Google Patents

Indolokarbonitryle jako selektywne modulatory receptora androgenowego

Info

Publication number
PL2875013T3
PL2875013T3 PL13758975T PL13758975T PL2875013T3 PL 2875013 T3 PL2875013 T3 PL 2875013T3 PL 13758975 T PL13758975 T PL 13758975T PL 13758975 T PL13758975 T PL 13758975T PL 2875013 T3 PL2875013 T3 PL 2875013T3
Authority
PL
Poland
Prior art keywords
indolecarbonitriles
androgen receptor
receptor modulators
selective androgen
selective
Prior art date
Application number
PL13758975T
Other languages
English (en)
Polish (pl)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Intellectual Property (No. 2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2875013(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (No. 2) Limited filed Critical Glaxosmithkline Intellectual Property (No. 2) Limited
Publication of PL2875013T3 publication Critical patent/PL2875013T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PL13758975T 2012-07-17 2013-07-15 Indolokarbonitryle jako selektywne modulatory receptora androgenowego PL2875013T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators
EP13758975.0A EP2875013B1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
PL2875013T3 true PL2875013T3 (pl) 2018-06-29

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13758975T PL2875013T3 (pl) 2012-07-17 2013-07-15 Indolokarbonitryle jako selektywne modulatory receptora androgenowego

Country Status (39)

Country Link
US (5) US8957104B2 (en:Method)
EP (1) EP2875013B1 (en:Method)
JP (1) JP6106746B2 (en:Method)
KR (1) KR102127939B1 (en:Method)
CN (1) CN104619693B (en:Method)
AR (1) AR091770A1 (en:Method)
AU (1) AU2013291721B2 (en:Method)
BR (1) BR112015000940B1 (en:Method)
CA (1) CA2879104C (en:Method)
CL (1) CL2015000119A1 (en:Method)
CO (1) CO7240378A2 (en:Method)
CR (1) CR20150008A (en:Method)
CY (1) CY1120064T1 (en:Method)
DK (1) DK2875013T3 (en:Method)
DO (1) DOP2015000004A (en:Method)
EA (1) EA026371B8 (en:Method)
ES (1) ES2657912T3 (en:Method)
HR (1) HRP20180061T1 (en:Method)
HU (1) HUE036238T2 (en:Method)
IL (1) IL236448A (en:Method)
IN (1) IN2014KN02993A (en:Method)
JO (1) JO3384B1 (en:Method)
LT (1) LT2875013T (en:Method)
ME (1) ME02996B (en:Method)
MX (1) MX349943B (en:Method)
MY (2) MY173845A (en:Method)
NZ (1) NZ703129A (en:Method)
PE (1) PE20150371A1 (en:Method)
PH (1) PH12015500104B1 (en:Method)
PL (1) PL2875013T3 (en:Method)
PT (1) PT2875013T (en:Method)
RS (1) RS56810B1 (en:Method)
SG (1) SG11201408493WA (en:Method)
SI (1) SI2875013T1 (en:Method)
SM (1) SMT201800115T1 (en:Method)
TW (1) TWI574946B (en:Method)
UY (1) UY34911A (en:Method)
WO (1) WO2014013309A1 (en:Method)
ZA (1) ZA201500096B (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
HRP20180061T1 (hr) * 2012-07-17 2018-02-23 Glaxosmithkline Intellectual Property (No. 2) Limited Indolkarbonitrili kao selektivni modulatori androgenskih receptora
US9902694B2 (en) * 2014-01-21 2018-02-27 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Crystalline forms
KR20190077607A (ko) * 2014-10-16 2019-07-03 지티엑스, 인코포레이티드 Sarm을 이용하는 비뇨기 장애의 치료 방법
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000552A2 (en) 1998-02-25 2001-04-30 Genetics Inst Inhibitors of phospholipase enzymes
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
DK1511724T3 (da) 2002-05-24 2014-06-16 Bayer Cropscience Ag Fremgangsmåde til fremstilling af thioalkylaminderivater
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CA2564952A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
ATE525354T1 (de) 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
EP1756109B1 (en) 2004-05-03 2016-07-13 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
CN1993321A (zh) * 2004-06-01 2007-07-04 弗·哈夫曼-拉罗切有限公司 作为单胺再摄取抑制剂的3－氨基－1－芳基丙基吲哚类化合物
NZ565363A (en) * 2005-07-29 2010-03-26 Pfizer Prod Inc Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
BRPI0709612A2 (pt) * 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
JP5275236B2 (ja) * 2006-09-29 2013-08-28 スミスクライン ビーチャム コーポレーション 置換されたインドール化合物
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
CN102574860A (zh) * 2009-10-15 2012-07-11 辉瑞大药厂 吡咯并[2,3-d]嘧啶化合物
ES2461967T3 (es) * 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN103384661B (zh) * 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂
SI2796460T1 (sl) * 2011-12-21 2018-10-30 Jiangsu Hengrui Medicine Co. Ltd Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
HRP20180061T1 (hr) 2012-07-17 2018-02-23 Glaxosmithkline Intellectual Property (No. 2) Limited Indolkarbonitrili kao selektivni modulatori androgenskih receptora
US9902694B2 (en) * 2014-01-21 2018-02-27 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED Crystalline forms

Also Published As

Publication number Publication date
UY34911A (es) 2014-02-28
US11299457B2 (en) 2022-04-12
PH12015500104A1 (en) 2015-03-02
DK2875013T3 (en) 2018-01-22
US20190127326A1 (en) 2019-05-02
US20200270210A1 (en) 2020-08-27
JP2015522603A (ja) 2015-08-06
MY173845A (en) 2020-02-24
ZA201500096B (en) 2017-07-26
EA201492237A1 (ru) 2015-06-30
JO3384B1 (ar) 2019-03-13
BR112015000940A2 (pt) 2017-06-27
US20140024694A1 (en) 2014-01-23
SI2875013T1 (en) 2018-03-30
US20150080449A1 (en) 2015-03-19
HRP20180061T1 (hr) 2018-02-23
KR20150032333A (ko) 2015-03-25
CL2015000119A1 (es) 2015-04-24
SMT201800115T1 (it) 2018-03-08
DOP2015000004A (es) 2015-03-15
US10710963B2 (en) 2020-07-14
TWI574946B (zh) 2017-03-21
PE20150371A1 (es) 2015-03-27
JP6106746B2 (ja) 2017-04-05
PT2875013T (pt) 2018-02-28
RS56810B1 (sr) 2018-04-30
HUE036238T2 (hu) 2018-06-28
EA026371B1 (ru) 2017-03-31
ME02996B (me) 2018-10-20
AU2013291721A1 (en) 2015-02-26
MY198512A (en) 2023-09-01
PH12015500104B1 (en) 2015-03-02
CY1120064T1 (el) 2018-12-12
MX349943B (es) 2017-08-21
LT2875013T (lt) 2018-02-26
EA026371B8 (ru) 2017-06-30
BR112015000940B1 (pt) 2022-05-17
ES2657912T3 (es) 2018-03-07
US20170073309A1 (en) 2017-03-16
CR20150008A (es) 2015-03-09
CN104619693A (zh) 2015-05-13
HK1208867A1 (en) 2016-03-18
AR091770A1 (es) 2015-02-25
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
CO7240378A2 (es) 2015-04-17
US10196353B2 (en) 2019-02-05
CN104619693B (zh) 2019-08-13
IL236448A (en) 2016-10-31
MX2015000825A (es) 2015-07-17
EP2875013A1 (en) 2015-05-27
WO2014013309A1 (en) 2014-01-23
US9533948B2 (en) 2017-01-03
CA2879104A1 (en) 2014-01-23
AU2013291721B2 (en) 2016-02-25
SG11201408493WA (en) 2015-02-27
IN2014KN02993A (en:Method) 2015-05-08
CA2879104C (en) 2020-08-25
US8957104B2 (en) 2015-02-17
EP2875013B1 (en) 2017-11-29
IL236448A0 (en) 2015-02-26
KR102127939B1 (ko) 2020-06-29

Similar Documents

Publication Publication Date Title
IL262218A (en) Modulation of androgen receptor expression
GB201213700D0 (en) Receptor antagnists II
ME03081B (me) Modulatora receptora androgena patentni zahtevi
ZA201406390B (en) Liver x receptor modulators
EP2911666A4 (en) MODULATORS OF A RESISTANT ANDROGEN RECEPTOR
AP2014007548A0 (en) Selective androgen receptor modulators
ZA201500096B (en) Indolecarbonitriles as selective androgen receptor modulators
ZA201406326B (en) Liver x receptor modulators
IL239076A0 (en) Novel and selective androgen receptor modulators
GB201223053D0 (en) Receptor
PT3345899T (pt) Derivados de benzofurano-2-sulfonamida como moduladores dos receptores de quimioquinas
HK1196825A (en) Selective androgen receptor modulators
GB201207002D0 (en) appedUpR smartphone app
GB201206614D0 (en) appedUpR smartphone app